# The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breas

Source: https://onco.cc/trials/nct06140576/  
OnCo record `nct06140576` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of nab-paclitaxel and lenvatinib in triple-negative breast cancer, run by Zhejiang Cancer Hospital, not yet recruiting.

## Summary

The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial. is a phase 1/2, interventional study registered as NCT06140576 by Zhejiang Cancer Hospital, with a registry enrolment figure of 58 participants, started 2023-11-30 and due to reach its primary completion in 2025-12-31. Interventions recorded: Sindilimab; Nab-paclitaxel; Lenvatinib. Conditions listed: Breast Neoplasms. Triple-negative eligibility wording from the registry: "According to the definition of the latest ASCO/CAP guidelines, recurrent metastatic triple negative invasive breast cancer confirmed by histopathology meets the following conditions according to recent and previous pathological results: HER2 negative: IHC 0/1+or IHC2+but ISH is negative; ER negative". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06140576
- Phase: 1/2
- Setting: The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.
- Sponsor: Zhejiang Cancer Hospital
- Enrolled: 58

## Sources

- ClinicalTrials.gov NCT06140576: https://clinicaltrials.gov/study/NCT06140576

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06140576.json